Blackstone to invest up to $250 million in British biotech company Autolus

Binance
Blackstone to invest up to $250 million in British biotech company Autolus
Blackstone to invest up to 250 million in British biotech


Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said. Of the total investment, as much as $150 million will support the development and commercialization of obecabtagene autoleucel, a cell therapy that targets a condition called acute lymphoblastic leukemia. London-based Autolus
AUTL,
-1.59%
will receive $50 million of that upfront, with the rest to be paid as the company achieves certain milestones. In return, Blackstone’s life-sciences unit will receive a portion of the therapy’s royalties.



Source link

Be the first to comment

Leave a Reply

Your email address will not be published.


*